Tumor budding and poorly differentiated clusters as a biological continuum in colorectal cancer invasion and prognosis.

Journal: Scientific reports
Published Date:

Abstract

Tumor budding (TB) and poorly differentiated clusters (PDCs) are features of infiltrative growth patterns and powerful independent prognostic factors in colorectal cancer (CRC), yet the underlying biological mechanisms behind their role in CRC invasion is less understood. The aim of this study was to investigate the molecular background and prognostic role of tumor cluster size at the invasive margin (IM) of CRC, and determine whether a biological continuum between TB and PDCs exists. Using a combination of spatial transcriptomic and immunohistochemical (IHC) techniques, we demonstrated a biological continuum from larger to smaller tumor clusters, with TB possessing greater invasive potential than PDCs. We deployed artificial intelligence on a cohort of 1134 Stage I-III CRC resections to automatically detect nearly 400,000 isolated tumor cells/clusters of any particular size across the IM. We determined that 2-celled clusters were the most abundant feature at the IM, and the simultaneous assessment of TB and PDCs yielded a prognostic performance stronger than either independently. Our study provides a deeper understanding of the mechanisms behind CRC invasion while improving risk stratification for Stage I-III CRC.

Authors

  • Tariq Sami Haddad
    Radboud University Medical Center, Nijmegen, Netherlands. tariq.haddad@radboudumc.nl.
  • John-Melle Bokhorst
    Diagnostic Image Analysis Group and the Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Luuk van den Dobbelsteen
    Radboud University Medical Center, Nijmegen, Netherlands.
  • Sonay K Öztürk
    Radboud University Medical Center, Nijmegen, Netherlands.
  • Elias Baumann
    Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
  • Shannon van Vliet
    Radboud University Medical Center, Nijmegen, Netherlands.
  • Kiek Verrijp
    Department of Medical BioSciences, Radboudumc, Nijmegen, The Netherlands.
  • Nigel B Jamieson
    Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Colin Wood
    Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Martin D Berger
    Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Richard Kirsch
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Marco Aben
    Radboud University Medical Center, Nijmegen, Netherlands.
  • Natasja Rutgers
    Radboud University Medical Center, Nijmegen, Netherlands.
  • Hideki Ueno
    Department of Surgery, National Defense Medical College, Saitama, Japan.
  • Francesco Ciompi
    Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: francesco.ciompi@radboudumc.nl.
  • Femke Simmer
    Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Jeroen van der Laak
    Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Alessandro Lugli
    Institute of Pathology, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland.
  • Inti Zlobec
    Institute of Pathology, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland. inti.zlobec@pathology.unibe.ch.
  • Iris Nagtegaal
    Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.